The author is at the Rockefeller University, New York, New York 10021, USA. darnell@rockefeller.edu
The transcription factor STAT3 is overactive in many tumors and has attracted attention as a drug target. But in vivo evidence suggesting that inhibiting STAT3 could counteract cancer has been incomplete. The picture in the whole animal now begins to clarify, and it bodes well for this approach (pages 623−629).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
